Japan does have multiple registered treatment plans

MHLW's e-Regenerative Medicine registry lists third-category cancer treatment plans using NK cells, NKT/γδT cells and dendritic-cell vaccines. This shows that these services exist within a defined regulatory framework.

Registration is not a universal efficacy endorsement

A submitted plan, committee review or self-pay availability does not mean that efficacy is established for every tumor type at the level of standard care. Cell processing, combinations, eligibility and outcome reporting vary across providers.

Some approaches are still being tested as research

Shizuoka Cancer Center has a Phase I study of a neoantigen-specific dendritic-cell vaccine in recurrent solid tumors. Phase I primarily addresses early safety and feasibility questions; it is not equivalent to established standard-of-care efficacy.

Six questions to ask

Is this a clinical study or a registered treatment service?
What tumor type, stage and biomarkers are targeted?
How is it combined with standard treatment?
What objective response, survival or quality-of-life evidence is published?
What is the total cost and travel burden?
How are cell manufacturing, quality control and adverse events managed?

LINK MT policy: We neither market immune-cell therapy as universally effective nor dismiss it as a category. We place standard care, second opinions and trials first, then assess an individualized treatment against evidence and purpose.

LINK MT supports evidence review, record preparation and coordination. Diagnosis, treatment and acceptance are decided by medical providers.

Primary and official sources

Japan medical enquiry